Overview

Also Known As: NOD-scid IL2Rgamma^null, NOD-scid IL2Rg^null, NSG, NOD scid gamma

These mice are most often referred to using their branded name "NSG™" and are extremely immunodeficient. The mice carry two mutations on the NOD/ShiLtJ genetic background; severe combined immune deficiency (scid) and a complete null allele of the IL2 receptor common gamma chain (IL2rg^null). The scid mutation is in the DNA repair complex protein Prkdc and renders the mice B and T cell deficient. The IL2rg^null mutation prevents cytokine signaling through multiple receptors, leading to a deficiency in functional NK cells. The severe immunodeficiency allows the mice to be humanized by engraftment of human CD34+ hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient derived xenografts (PDX), or adult stem cells and tissues. The immunodeficient NSG mice enable research in human immune function, infectious disease, diabetes, oncology, and stem cell biology.

Please click here to order our Humanized Mice

Donating Investigator

Dr. Leonard D. Shultz, The Jackson Laboratory

Genetic overview

Genetic Background	Generation
	Contact Technical Support (2018-07-27 00:00:00)

Prkdc^scid

Allele Type	Gene Symbol	Gene Name
Spontaneous	Prkdc	protein kinase, DNA activated, catalytic polypeptide

Il2rg^tm1Wjl

Allele Type	Gene Symbol	Gene Name
Targeted (Null/Knockout)	Il2rg	interleukin 2 receptor, gamma chain

View Genetics

Research Applications

Research Tools
Internal/Organ Research
Immunology, Inflammation and Autoimmunity Research
Virology Research
Cancer Research

View All Research Applications

Base Price

Starting at:

$170.00 Domestic price for male 3-week

View Price List

Volume Pricing Available!

for select shipping destinations

Click for Details

Details

Important Note

Like its parental strain, NOD/ShiLtJ (Stock No. 001976), NSG mice exhibit a progressive hearing loss that is already severe by three months of age.

Detailed Description

The NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ mice, most often known by their branded name, NOD scid gamma (NSG™), do not express the Prkdc gene nor the X-linked Il2rg gene. NSG mice are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. Histological examination of lymphoid tissues reveals absence of lymphoid cells and some cystic structures in the thymus, an absence of follicles in the spleen and markedly diminished celluarity of lymph nodes. NSG mice are deficient in mature lymphocytes, serum Ig is not detectable and natural killer (NK) cell cytotoxic activity is extremely low. These mice are resistant to lymphoma development even after sublethal irradiation treatment. These mutant mice have been shown to readily support engraftment of human CD34⁺ hematopoietic stem cells and represent a superior, long-lived model suitable for studies employing xenotransplantation strategies. NSG mice are highly sensitive to the diabetogenic effects of streptozotocin (STZ). The NSG-STZ preclinical model for pancreatic islet transplantation is now available from JAX® Services . Please note that the NSG carries the true null interleukin-2 receptor gamma chain mutation and should not be confused with other strains that express a truncated interleukin-2 receptor gamma chain as described in: "Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain" Ohbo K et al. Blood 1996. 87:956-67.

View our Resources for the NSG™ mouse model, including,

NSG™ Mouse Model Portfolio

Housing and Breeding Considerations for NSG™ Mice

Frequently Asked NSG™ Questions

Breakthrough Research Using NSG™

Immunodeficient Mouse and Xenograft Host Comparisons

Flow Cytometry Characterization Data for Immunodeficient JAX Strains

Development

These double mutant mice were produced by breeding female NOD.CB17-Prkdc^scid/J (Stock No. 001303) mice with male mice bearing the X-linked B6.129S4-Il2rg^tm1Wjl/J allele (Stock No. 003174). The resulting male mice heterozygous for the Prkdc^scid allele and hemizygous for the Il2rg^tm1Wjl allele were crossed to female NOD.CB17-Prkdc^scid/J (Stock No. 001303) mice for eight generations. Heterozygotes were interbred to produce mice homozygous for the Prkdc^scid allele and homozygous (females) or hemizygous (males) for the Il2rg^tm1Wjl allele.

Control Suggestions

001303 NOD.CB17-Prkdc^scid/J, ()
001976 NOD/ShiLtJ, ()

Additional Information

Considerations for Choosing Controls

Selected References

Shultz LD; Lyons BL; Burzenski LM; Gott B; Chen X; Chaleff S; Kotb M; Gillies SD; King M; Mangada J; Greiner DL; Handgretinger R. 2005. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174(10):6477-89PubMed: 15879151 MGI: J:109833
Coughlan AM; Harmon C; Whelan S; O'Brien EC; O'Reilly VP; Crotty P; Kelly P; Ryan M; Hickey FB; O'Farrelly C; Little MA. 2016. Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells Dev 25(7):530-41PubMed: 26879149 MGI: J:230785

View All References

Genetics

Prkdc^scid

Allele Symbol: Prkdc^scid

Allele Name	severe combined immunodeficiency
Allele Type	Spontaneous
Allele Synonym(s)	Prkdc^scid; severe combined immunodeficiency
Gene Symbol and Name	Prkdc, protein kinase, DNA activated, catalytic polypeptide
Gene Synonym(s)	AI326420; DNA-PK; DNA-PKcs; DNAPDcs; DNPK1; DOXNPH; doxorubicin nephropathy; DNAPK; expressed sequence AU019811; dxnph; dxnph; scid; IMD26; HYRC; HYRC1; p350; slip; XRCC7; severe combined immunodeficiency; expressed sequence AI326420; AU019811; DNA-PKC; DNAPKc
Site of Expression	T and B lymphocytes.
Strain of Origin	C.B-17
Chromosome	16
Molecular Note	A T-to-A transversion point mutation at a position corresponding to codon 4046 (codon 4095 in transcript ENSMUST00000023352.8) created a premature stop codon.

Il2rg^tm1Wjl

Allele Symbol: Il2rg^tm1Wjl

Allele Name	targeted mutation 1, Warren J Leonard
Allele Type	Targeted (Null/Knockout)
Allele Synonym(s)	Il2rg^tm1Wjl; targeted mutation 1, Warren J Leonard
Gene Symbol and Name	Il2rg, interleukin 2 receptor, gamma chain
Gene Synonym(s)	common cytokine receptor gamma chain; CIDX; IMD4; gc; IL-2RG; P64; [g]c; SCIDX; SCIDX1; common gamma chain; gamma C receptor; gamma(c); CD132; Ab2-183; Cd132; gammaC
Site of Expression	Primarily lymphoid cells.
Strain of Origin	129S4/SvJae
Chromosome	X
Molecular Note	A neomycin resistance cassette replaced part of exon 3 and all of exons 4 - 8 of the gene, resulting in the loss of most of the extracellular domain and all of the transmembrane and cytoplasmic domains of the protein.
Mutations Made By	Dr. Warren Leonard, NHLBI, NIH

Disease/Phenotype

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: Prkdc^scid related

Research Tools
- Toxicology Research
  - xenograft/transplant host
- Cancer Research
  - B and T cell deficiency, xenograft/transplant host
Internal/Organ Research
- Lymphoid Tissue Defects
  - B and T cell deficiency
Immunology, Inflammation and Autoimmunity Research
- Immunodeficiency
  - B and T cell deficiency
Virology Research
- B and T Cell Deficiency
  - AIDS research tool

Research Tools
- Immunology, Inflammation and Autoimmunity Research
  - B, T, and NK cell deficiency
- Infectious Disease
  - HIV

Genotype: Il2rg^tm1Wjl related

Cancer Research
- Growth Factors/Receptors/Cytokines
Immunology, Inflammation and Autoimmunity Research
- Growth Factors/Receptors/Cytokines

Mammalian Phenotype Terms by Genotype

The following phenotype relates to a compound genotype created using this strain

Genotype: Il2rg^tm1Wjl/Il2rg^tm1Wjl Prkdc^scid/Prkdc^scid
NOD.Cg-Prkdc Il2rg/Sz

cellular phenotype

increased cellular sensitivity to X-ray irradiation
- mice do not survive doses above or equal to 400cGy

homeostasis/metabolism phenotype

abnormal glucose homeostasis
- streptozotocin-diabetic mice are not restored to euglycemia after receiving transplants of 1000 to 3000 IEQ, while 4000 IEQ transplant was successful in two long-term survivors

hyperglycemia
- streptozotocin effectively induced hyperglycemia essentially equally in male and female mice at doses of 120to 160 mg/kg; some mice do not become hyperglycemic at all doses of streptozotocin administered

immune system phenotype

abnormal immune system organ morphology
- lymph tissues are severely depleted of lymphoid cells

abnormal response to transplant
- human CD45+ cells comprise almost 50% of cells in the spleen, approximately 35% in bone marrow and thymus, and 6% in blood at 10 weeks post-engraftment
- mice support CD34+ human stem cell engraftment at much higher levels than Prkdc^scid controls

abnormal spleen B cell follicle morphology
- spleens do not have detectable follicles

abnormal splenic cell ratio
- two fold reduction in nucleated spleen cell numbers in comparison to Prkdc^scid controls

abnormal thymus morphology
- thymus consists mostly of stromal cells with sporadic cyst structures

decreased CD4-positive, alpha beta T cell number
- spleens are deficient in mature T cells

decreased CD8-positive, alpha-beta T cell number
- spleens are deficient in mature T cells

decreased immature B cell number
- flow cytometric analysis indicates that spleen cells exhibit a reduction in B220+ IgK- immature B cells in comparison to Prkdc^scid controls

decreased immunoglobulin level
- no detectable immunoglobulin in mice at 394-426 days of age

decreased leukocyte cell number
- decrease in peripheral leukocytes at 10 weeks as compared to to Prkdc^scid controls

decreased mature B cell number
- spleens are deficient in B220+ IgK+ B cells

decreased NK cell number
- mice are deficient in cells expressing NK cell markers in comparison to Prkdc^scid controls
- spleen cells from poly(I:C) stimulated 6-8 week old mice exhibit very low levels of NK cell cytotoxic activity

lymph node hypoplasia
- lymph nodes are hypocellular

small lymph nodes
- lymph nodes in the double mutant are markedly smaller than those of homozygous Prkdc^scid mice

thymus cysts
- sporadic cyst structures

endocrine/exocrine gland phenotype

abnormal thymus morphology
- thymus consists mostly of stromal cells with sporadic cyst structures

thymus cysts
- sporadic cyst structures

mortality/aging

premature death
- median survival time is lengthened to between 59-95 weeks (median 89 weeks) in contrast to the shorter lifespan observed homozygous Prkdc^scid controls
- the majority of autopsies indicate no evidence of lymphomas

neoplasm

decreased incidence of tumors by ionizing radiation induction
- mice irradiated with doses below 400cGy do not exhibit thymic lymphomas in contrast to homozygous Prkdc^scid controls

hematopoietic system phenotype

abnormal spleen B cell follicle morphology
- spleens do not have detectable follicles

abnormal splenic cell ratio
- two fold reduction in nucleated spleen cell numbers in comparison to Prkdc^scid controls

abnormal thymus morphology
- thymus consists mostly of stromal cells with sporadic cyst structures

decreased CD4-positive, alpha beta T cell number
- spleens are deficient in mature T cells

decreased CD8-positive, alpha-beta T cell number
- spleens are deficient in mature T cells

decreased immature B cell number
- flow cytometric analysis indicates that spleen cells exhibit a reduction in B220+ IgK- immature B cells in comparison to Prkdc^scid controls

decreased immunoglobulin level
- no detectable immunoglobulin in mice at 394-426 days of age

decreased leukocyte cell number
- decrease in peripheral leukocytes at 10 weeks as compared to to Prkdc^scid controls

decreased mature B cell number
- spleens are deficient in B220+ IgK+ B cells

decreased mean corpuscular volume
- slight decrease in packed cell volume at 10 weeks as compared to to Prkdc^scid controls

decreased NK cell number
- mice are deficient in cells expressing NK cell markers in comparison to Prkdc^scid controls
- spleen cells from poly(I:C) stimulated 6-8 week old mice exhibit very low levels of NK cell cytotoxic activity

thymus cysts
- sporadic cyst structures

Genotype: Il2rg^tm1Wjl/Y Prkdc^scid/Prkdc^scid
NOD.Cg-Prkdc Il2rg/Sz

cellular phenotype

increased cellular sensitivity to X-ray irradiation
- mice do not survive doses above or equal to 400cGy

immune system phenotype

abnormal immune system organ morphology
- lymph tissues are severely depleted of lymphoid cells

abnormal response to transplant
- CD4:CD8 human T cell ratios that are close to normal physiological values and high levels of human B cells are observed in spleens of mice compared to NOD.CB17-Prkdc^scid mice
- engraftment of human lymphohematopoietic cells in blood and thymus, and peripheral blood mononuclear cells (PMBC) engraftment are higher than in NOD.CB17-Prkdc^scid
- human CD45+ cells comprise almost 50% of cells in the spleen, approximately 35% in bone marrow and thymus, and 6% in blood at 10 weeks post-engraftment
- irradiated mice engrafted with human hematopoietic stem cells (HSCs) show much greater engraftment of human hematopoietic cells at 12 weeks than control NOD.129S7(B6)-Rag1^tm1Mom homozygotes
- levels of human CD45+ cell and CD3+ T cell engraftment are higher in spleens than in NOD.CB17-Prkdc^scid mice
- mice support CD34+ human stem cell engraftment at much higher levels than Prkdc^scid controls
- percentages of human CD45+ cells engrafted in bone marrow are higher than in NOD.CB17-Prkdc^scid mice

abnormal spleen B cell follicle morphology
- spleens do not have detectable follicles

abnormal splenic cell ratio
- two fold reduction in nucleated spleen cell numbers in comparison to Prkdc^scid controls

abnormal thymus morphology
- thymus consists mostly of stromal cells with sporadic cyst structures

decreased CD4-positive, alpha beta T cell number
- spleens are deficient in mature T cells

decreased CD8-positive, alpha-beta T cell number
- spleens are deficient in mature T cells

decreased immature B cell number
- flow cytometric analysis indicates that spleen cells exhibit a reduction in B220+ IgK- immature B cells in comparison to Prkdc^scid controls

decreased immunoglobulin level
- no detectable immunoglobulin in mice at 394-426 days of age

decreased leukocyte cell number
- decrease in peripheral leukocytes at 10 weeks as compared to to Prkdc^scid controls

decreased mature B cell number
- spleens are deficient in B220+ IgK+ B cells

decreased NK cell number
- mice are deficient in cells expressing NK cell markers in comparison to Prkdc^scid controls
- spleen cells from poly(I:C) stimulated 6-8 week old mice exhibit very low levels of NK cell cytotoxic activity

lymph node hypoplasia
- lymph nodes are hypocellular

small lymph nodes
- lymph nodes in the double mutant are markedly smaller than those of homozygous Prkdc^scid mice

endocrine/exocrine gland phenotype

abnormal thymus morphology
- thymus consists mostly of stromal cells with sporadic cyst structures

hematopoietic system phenotype

abnormal spleen B cell follicle morphology
- spleens do not have detectable follicles

abnormal splenic cell ratio
- two fold reduction in nucleated spleen cell numbers in comparison to Prkdc^scid controls

abnormal thymus morphology
- thymus consists mostly of stromal cells with sporadic cyst structures

decreased CD4-positive, alpha beta T cell number
- spleens are deficient in mature T cells

decreased CD8-positive, alpha-beta T cell number
- spleens are deficient in mature T cells

decreased immature B cell number
- flow cytometric analysis indicates that spleen cells exhibit a reduction in B220+ IgK- immature B cells in comparison to Prkdc^scid controls

decreased immunoglobulin level
- no detectable immunoglobulin in mice at 394-426 days of age

decreased leukocyte cell number
- decrease in peripheral leukocytes at 10 weeks as compared to to Prkdc^scid controls

decreased mature B cell number
- spleens are deficient in B220+ IgK+ B cells

decreased mean corpuscular volume
- slight decrease in packed cell volume at 10 weeks as compared to to Prkdc^scid controls

decreased NK cell number
- mice are deficient in cells expressing NK cell markers in comparison to Prkdc^scid controls
- spleen cells from poly(I:C) stimulated 6-8 week old mice exhibit very low levels of NK cell cytotoxic activity

mortality/aging

premature death
- median survival time is lengthened to between 59-95 weeks (median 89 weeks) in contrast to the shorter lifespan observed homozygous Prkdc^scid controls
- the majority of autopsies indicate no evidence of lymphomas

Phenotype Information

Body Weight Information - JAX^® Mice Strain NOD.Cg-Prkdc^scid Il2rg^tm1Wyl/SzJ (005557)

JAX^® Physiological Data Summary [pdf]

References

Shultz LD; Lyons BL; Burzenski LM; Gott B; Chen X; Chaleff S; Kotb M; Gillies SD; King M; Mangada J; Greiner DL; Handgretinger R. 2005. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174(10):6477-89PubMed: 15879151 MGI: J:109833
Coughlan AM; Harmon C; Whelan S; O'Brien EC; O'Reilly VP; Crotty P; Kelly P; Ryan M; Hickey FB; O'Farrelly C; Little MA. 2016. Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells Dev 25(7):530-41PubMed: 26879149 MGI: J:230785

Additional References

King M; Pearson T; Shultz LD; Leif J; Bottino R; Trucco M; Atkinson MA; Wasserfall C; Herold KC; Woodland RT; Schmidt MR; Woda BA; Thompson MJ; Rossini AA; Greiner DL. 2008. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 126(3):303-14PubMed: 18096436 MGI: J:131635
Pearson T; Shultz LD; Lief J; Burzenski L; Gott B; Chase T; Foreman O; Rossini AA; Bottino R; Trucco M; Greiner DL. 2008. A new immunodeficient hyperglycaemic mouse model based on the Ins2 ( Akita ) mutation for analyses of human islet and beta stem and progenitor cell function. Diabetologia 51(8):1449-56PubMed: 18563383 MGI: J:138005
Pearson T; Shultz LD; Miller D; King M; Laning J; Fodor W; Cuthbert A; Burzenski L; Gott B; Lyons B; Foreman O; Rossini AA; Greiner DL. 2008. Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol 154(2):270-84PubMed: 18785974 MGI: J:140388
Quintana E; Shackleton M; Sabel MS; Fullen DR; Johnson TM; Morrison SJ. 2008. Efficient tumour formation by single human melanoma cells. Nature 456(7222):593-8PubMed: 19052619 MGI: J:142408
Kumar P; Ban HS; Kim SS; Wu H; Pearson T; Greiner DL; Laouar A; Yao J; Haridas V; Habiro K; Yang YG; Jeong JH; Lee KY; Kim YH; Kim SW; Peipp M; Fey GH; Manjunath N; Shultz LD; Lee SK; Shankar P. 2008. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134(4):577-86PubMed: 18691745 MGI: J:142409
Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F. 2008. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 123(9):2222-7PubMed: 18688847 MGI: J:142410
Ishikawa F; Yasukawa M; Lyons B; Yoshida S; Miyamoto T; Yoshimoto G; Watanabe T; Akashi K; Shultz LD; Harada M. 2005. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106(5):1565-73PubMed: 15920010 MGI: J:142411
Simpson-Abelson MR; Sonnenberg GF; Takita H; Yokota SJ; Conway TF Jr; Kelleher RJ Jr; Shultz LD; Barcos M; Bankert RB. 2008. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol 180(10):7009-18PubMed: 18453623 MGI: J:142412
Majeti R; Park CY; Weissman IL. 2007. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 1(6):635-45PubMed: 18371405 MGI: J:142413
Shultz LD; Ishikawa F; Greiner DL. 2007. Humanized mice in translational biomedical research. Nat Rev Immunol 7(2):118-30PubMed: 17259968 MGI: J:142414
Strowig T; Gurer C; Ploss A; Liu YF; Arrey F; Sashihara J; Koo G; Rice CM; Young JW; Chadburn A; Cohen JI; Munz C. 2009. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 206(6):1423-34PubMed: 19487422 MGI: J:149509
le Viseur C; Hotfilder M; Bomken S; Wilson K; Rottgers S; Schrauder A; Rosemann A; Irving J; Stam RW; Shultz LD; Harbott J; Jurgens H; Schrappe M; Pieters R; Vormoor J. 2008. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 14(1):47-58PubMed: 18598943 MGI: J:150328
Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F. 2008. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 22(6):1207-13PubMed: 18418410 MGI: J:150329
Distler E; Wolfel C; Kohler S; Nonn M; Kaus N; Schnurer E; Meyer RG; Wehler TC; Huber C; Wolfel T; Hartwig UF; Herr W. 2008. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice. Exp Hematol 36(4):451-63PubMed: 18261837 MGI: J:150330
Ishikawa F; Yoshida S; Saito Y; Hijikata A; Kitamura H; Tanaka S; Nakamura R; Tanaka T; Tomiyama H; Saito N; Fukata M; Miyamoto T; Lyons B; Ohshima K; Uchida N; Taniguchi S; Ohara O; Akashi K; Harada M; Shultz LD. 2007. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25(11):1315-21PubMed: 17952057 MGI: J:150331
Ishikawa F; Niiro H; Iino T; Yoshida S; Saito N; Onohara S; Miyamoto T; Minagawa H; Fujii S; Shultz LD; Harada M; Akashi K. 2007. The developmental program of human dendritic cells is operated independently of conventional myeloid and lymphoid pathways. Blood 110(10):3591-660PubMed: 17664352 MGI: J:150332
Ishikawa F; Shimazu H; Shultz LD; Fukata M; Nakamura R; Lyons B; Shimoda K; Shimoda S; Kanemaru T; Nakamura K; Ito H; Kaji Y; Perry AC; Harada M. 2006. Purified human hematopoietic stem cells contribute to the generation of cardiomyocytes through cell fusion. FASEB J 20(7):950-2PubMed: 16585061 MGI: J:150333
Hayakawa J; Hsieh MM; Uchida N; Phang O; Tisdale JF. 2009. Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice. Stem Cells 27(1):175-82PubMed: 18927475 MGI: J:150336
Giassi LJ; Pearson T; Shultz LD; Laning J; Biber K; Kraus M; Woda BA; Schmidt MR; Woodland RT; Rossini AA; Greiner DL. 2008. Expanded CD34+ human umbilical cord blood cells generate multiple lymphohematopoietic lineages in NOD-scid IL2rgamma(null) mice. Exp Biol Med (Maywood) 233(8):997-1012PubMed: 18653783 MGI: J:150337
Unsinger J; McDonough JS; Shultz LD; Ferguson TA; Hotchkiss RS. 2009. Sepsis-induced human lymphocyte apoptosis and cytokine production in 'humanized' mice. J Leukoc Biol 86(2):219-27PubMed: 19369639 MGI: J:151270
Pearson T; Greiner DL; Shultz LD. 2008. Creation of 'humanized' mice to study human immunity. Curr Protoc Immunol Chapter 15:Unit 15.21PubMed: 18491294 MGI: J:151386
Ishikawa F; Saito Y; Yoshida S; Harada M; Shultz LD. 2008. The differentiative and regenerative properties of human hematopoietic stem/progenitor cells in NOD-SCID/IL2rgamma(null) mice. Curr Top Microbiol Immunol 324:87-94PubMed: 18481454 MGI: J:151387
King MA; Covassin L; Brehm MA; Racki W; Pearson T; Leif J; Laning J; Fodor W; Foreman O; Burzenski L; Chase TH; Gott B; Rossini AA; Bortell R; Shultz LD; Greiner DL. 2009. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 157(1):104-18PubMed: 19659776 MGI: J:151390
Jaiswal S; Jamieson CH; Pang WW; Park CY; Chao MP; Majeti R; Traver D; van Rooijen N; Weissman IL. 2009. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2):271-85PubMed: 19632178 MGI: J:151391
Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD Jr; van Rooijen N; Weissman IL. 2009. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286-99PubMed: 19632179 MGI: J:151392
King M; Pearson T; Rossini AA; Shultz LD; Greiner DL. 2008. Humanized mice for the study of type 1 diabetes and beta cell function. Ann N Y Acad Sci 1150:46-53PubMed: 19120266 MGI: J:151393
Shultz LD; Pearson T; King M; Giassi L; Carney L; Gott B; Lyons B; Rossini AA; Greiner DL. 2007. Humanized NOD/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research. Ann N Y Acad Sci 1103:77-89PubMed: 17332083 MGI: J:151394
Koo GC; Hasan A; O'Reilly RJ. 2009. Use of humanized severe combined immunodeficient mice for human vaccine development. Expert Rev Vaccines 8(1):113-20PubMed: 19093778 MGI: J:151535
Mota J; Rico-Hesse R. 2009. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol 83(17):8638-45PubMed: 19535452 MGI: J:153922
Jaiswal S; Pearson T; Friberg H; Shultz LD; Greiner DL; Rothman AL; Mathew A. 2009. Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS One 4(10):e7251PubMed: 19802382 MGI: J:154110
Chen Q; Khoury M; Chen J. 2009. Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci U S A 106(51):21783-8PubMed: 19966223 MGI: J:155817
Sanchez PV; Perry RL; Sarry JE; Perl AE; Murphy K; Swider CR; Bagg A; Choi JK; Biegel JA; Danet-Desnoyers G; Carroll M. 2009. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 23(11):2109-17PubMed: 19626050 MGI: J:156920
Marodon G; Desjardins D; Mercey L; Baillou C; Parent P; Manuel M; Caux C; Bellier B; Pasqual N; Klatzmann D. 2009. High diversity of the immune repertoire in humanized NOD.SCID.gamma c-/- mice. Eur J Immunol 39(8):2136-45PubMed: 19572320 MGI: J:156921
Lepus CM; Gibson TF; Gerber SA; Kawikova I; Szczepanik M; Hossain J; Ablamunits V; Kirkiles-Smith N; Herold KC; Donis RO; Bothwell AL; Pober JS; Harding MJ. 2009. Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol 70(10):790-802PubMed: 19524633 MGI: J:156922
Vlad G; Stokes MB; Liu Z; Chang CC; Sondermeijer H; Vasilescu ER; Colovai AI; Berloco P; D'Agati VD; Ratner L; Cortesini R; Suciu-Foca N. 2009. Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc. Hum Immunol 70(9):663-9PubMed: 19501624 MGI: J:156923
Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP. 2010. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood 115(6):1175-84PubMed: 20008304 MGI: J:157729
Gorantla S; Makarov E; Finke-Dwyer J; Gebhart CL; Domm W; Dewhurst S; Gendelman HE; Poluektova LY. 2010. CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol 184(12):7082-91PubMed: 20495069 MGI: J:161304
Shultz LD; Saito Y; Najima Y; Tanaka S; Ochi T; Tomizawa M; Doi T; Sone A; Suzuki N; Fujiwara H; Yasukawa M; Ishikawa F. 2010. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A 107(29):13022-7PubMed: 20615947 MGI: J:162315
Goldstein AS; Huang J; Guo C; Garraway IP; Witte ON. 2010. Identification of a cell of origin for human prostate cancer. Science 329(5991):568-71PubMed: 20671189 MGI: J:162606
Holt N; Wang J; Kim K; Friedman G; Wang X; Taupin V; Crooks GM; Kohn DB; Gregory PD; Holmes MC; Cannon PM. 2010. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28(8):839-47PubMed: 20601939 MGI: J:162607
Doulatov S; Notta F; Eppert K; Nguyen LT; Ohashi PS; Dick JE. 2010. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol 11(7):585-93PubMed: 20543838 MGI: J:162608
Rowe J; Greenblatt RJ; Liu D; Moffat JF. 2010. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res 86(3):276-85PubMed: 20307580 MGI: J:162609
Banerjee P; Tripp A; Lairmore MD; Crawford L; Sieburg M; Ramos JC; Harrington W Jr; Beilke MA; Feuer G. 2010. Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. Blood 115(13):2640-8PubMed: 20124219 MGI: J:162610
Janes MR; Limon JJ; So L; Chen J; Lim RJ; Chavez MA; Vu C; Lilly MB; Mallya S; Ong ST; Konopleva M; Martin MB; Ren P; Liu Y; Rommel C; Fruman DA. 2010. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16(2):205-13PubMed: 20072130 MGI: J:162611
Heaney NB; Pellicano F; Zhang B; Crawford L; Chu S; Kazmi SM; Allan EK; Jorgensen HG; Irvine AE; Bhatia R; Holyoake TL. 2010. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 115(11):2241-50PubMed: 20068223 MGI: J:162612
Libby SJ; Brehm MA; Greiner DL; Shultz LD; McClelland M; Smith KD; Cookson BT; Karlinsey JE; Kinkel TL; Porwollik S; Canals R; Cummings LA; Fang FC. 2010. Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection. Proc Natl Acad Sci U S A 107(35):15589-94PubMed: 20713716 MGI: J:163745
Morisot S; Wayne AS; Bohana-Kashtan O; Kaplan IM; Gocke CD; Hildreth R; Stetler-Stevenson M; Walker RL; Davis S; Meltzer PS; Wheelan SJ; Brown P; Jones RJ; Shultz LD; Civin CI. 2010. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia 24(11):1859-66PubMed: 20739953 MGI: J:165977
Wunderlich M; Chou FS; Link KA; Mizukawa B; Perry RL; Carroll M; Mulloy JC. 2010. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24(10):1785-8PubMed: 20686503 MGI: J:166359
Liu C; Chen BJ; Deoliveira D; Sempowski GD; Chao NJ; Storms RW. 2010. Progenitor cell dose determines the pace and completeness of engraftment in a xenograft model for cord blood transplantation. Blood 116(25):5518-27PubMed: 20833978 MGI: J:167432
Boitano AE; Wang J; Romeo R; Bouchez LC; Parker AE; Sutton SE; Walker JR; Flaveny CA; Perdew GH; Denison MS; Schultz PG; Cooke MP. 2010. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329(5997):1345-8PubMed: 20688981 MGI: J:167433
Strowig T; Chijioke O; Carrega P; Arrey F; Meixlsperger S; Ramer PC; Ferlazzo G; Munz C. 2010. Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood 116(20):4158-67PubMed: 20671122 MGI: J:167434
Maykel J; Liu JH; Li H; Shultz LD; Greiner DL; Houghton J. 2014. NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer. Dig Dis Sci 59(6):1169-79PubMed: 24798995 MGI: J:227975

Additional - Il2rg^tm1Wjl related

Additional - Prkdc^scid related

Technical Support

Contact Technical Support

Genotyping Protocols
- End Point Analysis: Prkdc^scid End Point
- Probe: Il2rg^tm1Wjl-PROBE
- Standard PCR: Il2rg^tm1Wjl
- Genotyping resources and troubleshooting
Dietary Information
- LabDiet® 5K52 formulation (6% fat)
Breeding Considerations

This strain is a good breeder.

When maintaining a live colony, females that are homozygous for both the Prkdc^scid and Il2rg^tm1Wjl alleles are bred to males that are homozygous for Prkdc^scid and hemizygous for Il2rg^tm1Wjl (Il2rg is an X-linked gene). See our NSG husbandry information for additional details. SPF (specific pathogen-free) conditions are recommended. Also see additional NSG housing information.
- Additional Breeding and Husbandry Support
Appearance
- albino
  Related Genotype: A/A Tyr^c/Tyr^c
Citation
When using the NSG mouse strain in a publication, please cite the originating article(s) and include JAX stock #005557 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

Pricing & Availability

Readily Available

Domestic
International

Domestic Pricing for

Commercial & For-Profit

Not-For-Profit & Academic

International Pricing for

Commercial & For-Profit

Not-For-Profit & Academic

Live Mouse

Age

Genotype

Price

weeks

Volume Pricing Details

Domestic Commercial & For-Profit

QUANTITY	VOLUME PRICING
Volume pricing is not available for Domestic Commercial & For-Profit.

Domestic Not-For-Profit & Academic

QUANTITY	VOLUME PRICING
Volume pricing is not available for Domestic Not-For-Profit & Academic.

International Commercial & For-Profit

QUANTITY	VOLUME PRICING
Volume pricing is not available for International Commercial & For-Profit.

International Not-For-Profit & Academic

QUANTITY	VOLUME PRICING
Volume pricing is not available for International Not-For-Profit & Academic.

Volume Pricing Program
Quantities: Volume pricing is automatically applied when a minimum quantity per strain for a shipment is reached
Sexes: Sexes of the same strain may be combined to reach minimum quantity levels to receive the volume pricing
Shipment: All shipping destinations qualify

This strain is available from some international Charles River (CR) breeding facilities in Japan and/or Europe. For more information, see the Worldwide Distributor List for JAX® Mice.

Cryorecovery - Pricing

Service	Genotype	Price
	Homozygous for Prkdc<scid>, Homozygous females and Hemizygous males for Il2rg<tm1Wjl>

We will fulfill your order by providing at least two carriers for each strain ordered. The total number, sex, and genotypes provided will vary, although typically 8 or more animals are provided. Please check genotypes which will be recovered. While the genotypes of all animals produced will be communicated to you prior to scheduling shipment, the genotypes of animals provided may not reflect the mating scheme and genotypes described in the strain description. Animals are typically ready to ship in 11-14 weeks. If a second recovery is required to produce the minimum number of animals, then delivery time would increase to approximately 25 weeks. If we fail to produce animals of the correct genotype, you will not be charged. We cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

Terms Of Use

Terms of Use

General Terms and Conditions

Questions about Terms of Use

Additional Use Restrictions Apply

Research institutions require an MTA, companies require a (no fee) commercial use agreement prior to shipping.

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As: NOD-scid IL2Rgammanull, NOD-scid IL2Rgnull, NSG, NOD scid gamma

Donating Investigator

Genetic overview

Research Applications

Base Price

Volume Pricing Available!

Important Note

Detailed Description

Development

Control Suggestions

Additional Information

Selected References

Prkdcscid

Allele Symbol: Prkdcscid

Il2rgtm1Wjl

Allele Symbol: Il2rgtm1Wjl

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: Prkdcscid related

Genotype: Il2rgtm1Wjl related

Mammalian Phenotype Terms by Genotype

Genotype: Il2rgtm1Wjl/Il2rgtm1Wjl Prkdcscid/PrkdcscidNOD.Cg-Prkdc Il2rg/Sz

cellular phenotype

homeostasis/metabolism phenotype

immune system phenotype

endocrine/exocrine gland phenotype

mortality/aging

neoplasm

hematopoietic system phenotype

Genotype: Il2rgtm1Wjl/Y Prkdcscid/PrkdcscidNOD.Cg-Prkdc Il2rg/Sz

cellular phenotype

immune system phenotype

endocrine/exocrine gland phenotype

hematopoietic system phenotype

mortality/aging

Phenotype Information

References

Additional References

Additional - Il2rgtm1Wjl related

Additional - Prkdcscid related

Genotyping Protocols

Dietary Information

Breeding Considerations

Appearance

Citation

Animal Health Reports

Live Mouse

Volume Pricing Details

Domestic Commercial & For-Profit

Domestic Not-For-Profit & Academic

International Commercial & For-Profit

International Not-For-Profit & Academic

Cryorecovery - Pricing

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms of Use

Additional Use Restrictions Apply

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Also Known As: NOD-scid IL2Rgamma^null, NOD-scid IL2Rg^null, NSG, NOD scid gamma

Prkdc^scid

Allele Symbol: Prkdc^scid

Il2rg^tm1Wjl

Allele Symbol: Il2rg^tm1Wjl

Genotype: Prkdc^scid related

Genotype: Il2rg^tm1Wjl related

Genotype: Il2rg^tm1Wjl/Il2rg^tm1Wjl Prkdc^scid/Prkdc^scid
NOD.Cg-Prkdc Il2rg/Sz

Genotype: Il2rg^tm1Wjl/Y Prkdc^scid/Prkdc^scid
NOD.Cg-Prkdc Il2rg/Sz

Additional - Il2rg^tm1Wjl related

Additional - Prkdc^scid related